OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)
Amanda Tufman, Jens Neumann, Farkhad Manapov, et al.
Lung Cancer (2021) Vol. 160, pp. 17-27
Closed Access | Times Cited: 13
Amanda Tufman, Jens Neumann, Farkhad Manapov, et al.
Lung Cancer (2021) Vol. 160, pp. 17-27
Closed Access | Times Cited: 13
Showing 13 citing articles:
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
François Ghiringhelli, Frédéric Bibeau, Laurent Greillier, et al.
EBioMedicine (2023) Vol. 92, pp. 104633-104633
Open Access | Times Cited: 45
François Ghiringhelli, Frédéric Bibeau, Laurent Greillier, et al.
EBioMedicine (2023) Vol. 92, pp. 104633-104633
Open Access | Times Cited: 45
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
Francesco Cortiula, Bart Reymen, Solange Peters, et al.
Annals of Oncology (2022) Vol. 33, Iss. 9, pp. 893-908
Open Access | Times Cited: 63
Francesco Cortiula, Bart Reymen, Solange Peters, et al.
Annals of Oncology (2022) Vol. 33, Iss. 9, pp. 893-908
Open Access | Times Cited: 63
Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy
Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, et al.
Thoracic Cancer (2022) Vol. 13, Iss. 14, pp. 2031-2040
Open Access | Times Cited: 11
Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, et al.
Thoracic Cancer (2022) Vol. 13, Iss. 14, pp. 2031-2040
Open Access | Times Cited: 11
Spatial tertiary lymphoid structures imply response to anti‐PD ‐1 plus anlotinib in advanced non‐small cell lung cancer
Jianli Ma, Yuwei Deng, Minghui Zhang, et al.
Immunology (2024) Vol. 173, Iss. 3, pp. 536-551
Closed Access | Times Cited: 2
Jianli Ma, Yuwei Deng, Minghui Zhang, et al.
Immunology (2024) Vol. 173, Iss. 3, pp. 536-551
Closed Access | Times Cited: 2
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Current Oncology (2023) Vol. 30, Iss. 8, pp. 7499-7507
Open Access | Times Cited: 6
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Current Oncology (2023) Vol. 30, Iss. 8, pp. 7499-7507
Open Access | Times Cited: 6
A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
Valentina Bartolomeo, Francesco Cortiula, Lizza E.L. Hendriks, et al.
International Journal of Radiation Oncology*Biology*Physics (2023) Vol. 118, Iss. 5, pp. 1455-1460
Closed Access | Times Cited: 4
Valentina Bartolomeo, Francesco Cortiula, Lizza E.L. Hendriks, et al.
International Journal of Radiation Oncology*Biology*Physics (2023) Vol. 118, Iss. 5, pp. 1455-1460
Closed Access | Times Cited: 4
Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis
Sunyin Rao, Min Li, Jie Zhao, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 1
Sunyin Rao, Min Li, Jie Zhao, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 1
Polypectomy for Diminutive and Small Colorectal Polyps
Melissa Zarandi‐Nowroozi, Roupen Djinbachian, Daniel von Renteln
Gastrointestinal Endoscopy Clinics of North America (2022) Vol. 32, Iss. 2, pp. 241-257
Closed Access | Times Cited: 3
Melissa Zarandi‐Nowroozi, Roupen Djinbachian, Daniel von Renteln
Gastrointestinal Endoscopy Clinics of North America (2022) Vol. 32, Iss. 2, pp. 241-257
Closed Access | Times Cited: 3
Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy
Jan Nicolai Wagner, J. Roeper, Lukas C. Heukamp, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 688-688
Open Access
Jan Nicolai Wagner, J. Roeper, Lukas C. Heukamp, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 688-688
Open Access
Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer
Arnaud Colomb, Benoît Allignet, Mehdi Lamkhioued, et al.
Radiation Oncology (2024) Vol. 19, Iss. 1
Open Access
Arnaud Colomb, Benoît Allignet, Mehdi Lamkhioued, et al.
Radiation Oncology (2024) Vol. 19, Iss. 1
Open Access
The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
Marie-Hélène Denault, Cheryl Ho
Translational Cancer Research (2023) Vol. 12, Iss. 3, pp. 680-683
Open Access | Times Cited: 1
Marie-Hélène Denault, Cheryl Ho
Translational Cancer Research (2023) Vol. 12, Iss. 3, pp. 680-683
Open Access | Times Cited: 1
TFG-β Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer
Nuria Cárdenas-Quesada, Leticia Díaz-Beltrán, Carmen Rosa‐Garrido, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13780-13780
Open Access | Times Cited: 1
Nuria Cárdenas-Quesada, Leticia Díaz-Beltrán, Carmen Rosa‐Garrido, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13780-13780
Open Access | Times Cited: 1
Evaluation of the prognostic impact of SP263-evaluated PD-L1 expression in patients with non-small cell lung cancer (NSCLC) stage III treated with radio-chemotherapy
Jan Wagner, J. Roeper, Lukas C. Heukamp, et al.
Research Square (Research Square) (2022)
Open Access
Jan Wagner, J. Roeper, Lukas C. Heukamp, et al.
Research Square (Research Square) (2022)
Open Access
